{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:41:16Z","timestamp":1787510476320,"version":"build-2736575974"},"reference-count":25,"publisher":"BMJ","issue":"5","funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The laser in glaucoma and ocular hypertension (LiGHT) trial aims to establish whether initial treatment with selective laser trabeculoplasty (SLT) is superior to initial treatment with topical medication for primary open angle glaucoma (POAG) or ocular hypertension (OHT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>LiGHT is a prospective unmasked, multicentre, pragmatic, randomised controlled trial (RCT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>718 previously untreated patients with POAG or OHT were recruited at 6 UK centres between 2012 and 2014.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were randomised to initial SLT followed by medical therapy or medical therapy without laser. Participants will be monitored for 3 years, according to routine clinical practice. The primary outcome is EQ-5D-5L. Secondary outcomes are treatment pathway cost and cost-effectiveness, Glaucoma Utility Index (GUI), Glaucoma Symptom Scale, Glaucoma Quality of Life (GQL), pathway effectiveness, visual function, safety and concordance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 555 patients had POAG and 163 OHT; 518 patients had both eyes eligible. The mean age for patients with POAG was 64 years and for OHT 58 years. 70% of all participants were white. Median IOP for OHT eyes was 26\u2009mm Hg and 23\u2009mm Hg for POAG eyes. Median baseline visual field mean deviation was \u22120.81\u2009dB for OHT eyes and \u22122.82\u2009dB for POAG eyes. There was no difference between patients with POAG and patients with OHT on the EQ-5D-5DL; the difference between OHT and POAG on the GUI was \u22120.02 and 1.23 on the GQL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The LiGHT trial is the first RCT to compare the two treatment options in a real-world setting. The baseline characteristics of the LiGHT cohort compare well with other landmark glaucoma studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.isrctn.com\/ISRCTN32038223\" ext-link-type=\"uri\">ISRCTN32038223<\/jats:ext-link>\n                      , Pre-results.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bjophthalmol-2017-310870","type":"journal-article","created":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T20:50:26Z","timestamp":1507236626000},"page":"599-603","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":27,"title":["The Laser in Glaucoma and Ocular Hypertension (LiGHT) trial. A multicentre randomised controlled trial: baseline patient characteristics"],"prefix":"10.1136","volume":"102","author":[{"given":"Evgenia","family":"Konstantakopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gus","family":"Gazzard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Vickerstaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Nathwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Ambler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catey","family":"Bunce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,10,5]]},"reference":[{"key":"2020050713011094000_102.5.599.1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2010.122"},{"key":"2020050713011094000_102.5.599.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(00)00538-9"},{"key":"2020050713011094000_102.5.599.3","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.121.1.48"},{"key":"2020050713011094000_102.5.599.4","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.6.701"},{"key":"2020050713011094000_102.5.599.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.01.021"},{"key":"2020050713011094000_102.5.599.6","doi-asserted-by":"crossref","unstructured":"Gazzard G , Konstantakopoulou E , Garway-Heath D , et al . The Laser in Glaucoma and Ocular Hypertension Trial. A multicentre randomised controlled trial: design and methodology. BJO In Press 2017.","DOI":"10.1136\/bjophthalmol-2017-310877"},{"key":"2020050713011094000_102.5.599.7","unstructured":"National Institute for Health and Clinical Excellence. NICE: guidance on glaucoma: diagnosis and management of chronic open angle glaucoma and ocular hypertension: DoH, 2010. www.nice.org.uk\/CG85fullguideline."},{"key":"2020050713011094000_102.5.599.8","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"2020050713011094000_102.5.599.9","doi-asserted-by":"crossref","unstructured":"Devlin NJ , Shah KK , Feng Y , et al . Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ 2017.doi:10.1002\/hec.3564","DOI":"10.1002\/hec.3564"},{"key":"2020050713011094000_102.5.599.10","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/cmi027"},{"key":"2020050713011094000_102.5.599.11","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0b013e3181339f30"},{"key":"2020050713011094000_102.5.599.12","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.116.7.861"},{"key":"2020050713011094000_102.5.599.13","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200304000-00009"},{"key":"2020050713011094000_102.5.599.14","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1016\/j.ophtha.2013.07.054","article-title":"The United Kingdom Glaucoma Treatment Study: a multicenter, randomized, double-masked, placebo-controlled trial: baseline characteristics","volume":"120","author":"Lascaratos","year":"2013","journal-title":"Ophthalmology"},{"key":"2020050713011094000_102.5.599.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(98)97012-9"},{"key":"2020050713011094000_102.5.599.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)90147-1"},{"key":"2020050713011094000_102.5.599.17","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.117.5.573"},{"key":"2020050713011094000_102.5.599.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)90497-9"},{"key":"2020050713011094000_102.5.599.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(02)01167-3"},{"key":"2020050713011094000_102.5.599.20","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-012-0322-4"},{"key":"2020050713011094000_102.5.599.21","unstructured":"Szende A , Janssen B , Cabases J . eds. Self-reported population health: an international perspective based on EQ-5D. London: Springer Open, 2014."},{"key":"2020050713011094000_102.5.599.22","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(16)30956-4","article-title":"Effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma (EAGLE): a randomised controlled trial","volume":"388","author":"Azuara-Blanco","year":"2016","journal-title":"Lancet"},{"key":"2020050713011094000_102.5.599.23","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-0559"},{"key":"2020050713011094000_102.5.599.24","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e3181752c83"},{"key":"2020050713011094000_102.5.599.25","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2010.133"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2017-310870","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T04:55:53Z","timestamp":1601096153000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2017-310870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,5]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,4,19]]},"published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1136\/bjophthalmol-2017-310870"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310870","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,5]]}}}